Allogene Therapeutics vs Artiva Biotherapeutics
ALLO and ARTV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLO and ARTV compare
Allogene Therapeutics is the larger company, worth 1.6 times as much as Artiva Biotherapeutics ($311M against $199M).
Artiva Biotherapeutics scores higher on the StockData Score (8 against 3 for Allogene Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLO | ARTV |
|---|---|---|
| Size and price | ||
| Market cap | $311M | $199M |
| Share price | $0.900 | $4.07 |
| Change, 1 year | −23.7% | 11.2% |
| Change, 5 years | −95.2% | – |
| Beta (5Y) | 1.62 | 2.32 |
| Employees | 152 | 104 |
| StockData Score | ||
| Total score | 3 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.8× | 0.6× (better) |
| FCF yield | −35.0% (better) | −43.5% |
| Profitability | ||
| Return on equity | −49.3% | −43.6% (better) |
| Return on invested capital | −718% (better) | −2120% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −142.5× | – |
| Current ratio | 7.79 | 19.88 (better) |
| Altman Z-score | −4.92 | 3.77 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 90.5% | 83.2% |
| Held by insiders | 15.0% | 68.3% |
| Insider net buying, 12 months | −$668K | $106M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 17.5% | 19.0% |
Go deeper
- ALLO stock overview
- ALLO income statement
- ALLO valuation and score
- ARTV stock overview
- ARTV income statement
- ARTV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.